- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05127707
Strategies to Reduce Addiction Stigma Among Health Professionals
8 listopada 2021 zaktualizowane przez: Johns Hopkins Bloomberg School of Public Health
Effect of Exposure to Visual Campaigns and Narrative Vignettes on Addiction Stigma Among Health Professionals: A Randomized Experiment
The aim of this study was to evaluate the effects of exposure to stigma reduction message frames communicated by visual campaigns and narrative vignettes among a national sample of health professionals.
Przegląd badań
Status
Zakończony
Interwencja / Leczenie
- Behawioralne: Words Matter - Visual Campaign
- Behawioralne: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
- Behawioralne: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
- Behawioralne: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
- Behawioralne: Medication Treatment for Opioid Use Disorder Works - Visual Campaign
- Behawioralne: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
- Behawioralne: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)
- Behawioralne: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Szczegółowy opis
This randomized experiment evaluated the impact of exposure to message frames communicating the importance of non-stigmatizing language regarding addiction and the effectiveness of medication treatment for opioid use disorder delivered through a visual campaign alone or through a visual campaign in addition to a narrative vignette from the perspective of one of three messengers (a person with opioid use disorder, a clinician, or a health system leader) on attitudes toward people with opioid use disorder and medications for treating opioid use disorder among a national sample of health professionals.
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
1842
Faza
- Nie dotyczy
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21205
- Johns Hopkins Bloomberg School of Public Health
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Tak
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- employed as health professional in the United States, including clinicians (e.g., physicians, nurses, physician assistants, pharmacists, and optometrists), technicians and technologists (e.g., laboratory technologist or technician, emergency medical technician, paramedic, licensed practical or licensed vocational nurse, medical records or health information technician, etc.), health aids and assistants (e.g., nursing aide, home health aide, medical assistant, pharmacy aide, phlebotomist, etc.)
- participant in existing web-based survey panel (IPSOS's KnowledgeNetworks panel and partner opt-in panel)
Exclusion Criteria:
- not employed in health profession
- not able to complete experiment and survey in English
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Inny
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Brak interwencji: No exposure control group
This group was not exposed to any message frame.
|
|
|
Eksperymentalny: Words Matter - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
|
|
Eksperymentalny: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a person with opioid use disorder.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
|
|
Eksperymentalny: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a clinician.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
|
|
Eksperymentalny: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a health system administrator/leader.
|
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
|
|
Eksperymentalny: Medication Treatment Works - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
|
|
Eksperymentalny: Medication Treatment Works - Visual Campaign & Narrative Vignette (Person with OUD)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a person with opioid use disorder.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
|
|
Eksperymentalny: Medication Treatment Works - Visual Campaign & Narrative Vignette (Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a clinician.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
|
|
Eksperymentalny: Medication Treatment Works - Visual Campaign & Narrative Vignette (Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a health system administrator/leader.
|
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Rating of willingness to have person with opioid use disorder marry into their family
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder marry into the family.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of willingness to have person with opioid use disorder as a neighbor
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder as a neighbor.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of agreement that opioid use disorder is a medical condition
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement with statement "Opioid use disorder is a chronic medical condition like diabetes mellitus" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of agreement that individuals with opioid use disorder are to blame
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement with statement "Individuals with opioid use disorder only have themselves to blame for their problem" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of support for increasing government spending on opioid use disorder treatment
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of support for increasing government spending on treatment of opioid use disorder with 5 indicating strongly favoring and 1 indicating strongly opposing.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Feeling thermometer measure of warmth toward people with opioid use disorder
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of warmth felt toward people with opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Stigmatizing Language - Addict
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "addict" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - Substance abuse
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "substance abuse" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - dirty
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "'dirty' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - clean
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "'clean' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - addicted baby
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "addicted baby" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - person with substance use disorder
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "person with substance use disorder" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - substance use
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "substance use" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - negative test result
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "negative test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - positive test result
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "positive test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Stigmatizing Language - baby born with neonatal opioid withdrawal syndrome
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement that term "baby born with neonatal opioid withdrawal syndrome" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Willingness to sign pledge committing to using non-stigmatizing language
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Binary (yes/no) measure of whether participant is willing to sign a pledge committing to using non-stigmatizing language related to substance use disorder in clinical settings.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Perception of opioid use disorder treatment effectiveness
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Participant perception of whether there is a treatment for opioid use disorder that is effective for a long period of time (three close-ended response options: yes, there is a treatment; no, there isn't such a treatment; don't know).
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of willingness to have person taking medication marry into their family
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of willingness to have person taking medication to treat opioid use disorder marry into family.
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder marry into the family.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of willingness to have person taking medication marry as a neighbor
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of willingness to have person taking medication to treat opioid use disorder as a neighbor.
Item from the Social Distance Scale that measures one element of stigma (desire for social distance).
Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder as a neighbor.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of strength/weakness of person taking medication
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of strength/weakness of person taking medication to treat opioid use disorder on 5-point Likert scale with 5 indicating strong and 1 indicating weak.
This is a semantic differential measure.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Rating of agreement that recovery is possible
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of agreement with statement "Most people with opioid use disorder will, with medication treatment, get well and return to productive lives" on a 5-point Likert scale with 5 indicating strongly disagree and 1 indicating strongly agree.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
|
Feeling thermometer measure of warmth toward people taking medication
Ramy czasowe: Measured immediately post-exposure to message frame intervention
|
Rating of warmth felt toward people taking medication to treat opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm.
Measured via survey questionnaire.
|
Measured immediately post-exposure to message frame intervention
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Śledczy
- Główny śledczy: Alene Kennedy-Hendricks, PhD, Johns Hopkins Bloomberg School of Public Health
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
13 listopada 2020
Zakończenie podstawowe (Rzeczywisty)
30 listopada 2020
Ukończenie studiów (Rzeczywisty)
30 listopada 2020
Daty rejestracji na studia
Pierwszy przesłany
28 października 2021
Pierwszy przesłany, który spełnia kryteria kontroli jakości
8 listopada 2021
Pierwszy wysłany (Rzeczywisty)
19 listopada 2021
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
19 listopada 2021
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
8 listopada 2021
Ostatnia weryfikacja
1 listopada 2021
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Zaburzenia psychiczne
- Zaburzenia wywołane chemicznie
- Procesy patologiczne
- Zaburzenia związane z narkotykami
- Zaburzenia związane z substancjami
- Choroba
- Zaburzenia związane z opioidami
- Fizjologiczne skutki leków
- Depresanty ośrodkowego układu nerwowego
- Agenty obwodowego układu nerwowego
- Środki przeciwbólowe
- Agenci systemu sensorycznego
- Narkotyki
- Leki przeciwbólowe, Opioidy
Inne numery identyfikacyjne badania
- IRB14743
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
NIE
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Nie
Bada produkt urządzenia regulowany przez amerykańską FDA
Nie
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .